Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| IREN | Tempus AI | Fabrinet | |
|---|---|---|---|
| Moat rating | none The FY2026 10-K (filed 2026-08-27) shows IREN holds an input the industry competes on: it names 'access to secured and energized power' first among what it believes are the principal competitive factors in its industry, and reports 'executed grid connection agreements, letters of agreement or equivalents representing approximately 5GW of total power capacity' in the United States, Canada, Spain and Australia as of June 30, 2026. It does not claim an advantage over rivals in that input. It says 'Certain competitors may have access to more competitively priced power, a greater access to power and a better capacity to timely secure grid connections,' and 'Many of our competitors have greater financial, technical or commercial resources, longer cloud operating histories or larger customer bases, compared to us.' Operating AI Cloud Services capacity was approximately 40MW at June 30, 2026, and the stored XBRL fundamentals from this 10-K show an FY2026 operating loss of about $1,046.7M on revenue of about $707.0M, so no durable advantage is yet demonstrated. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." | narrow The FY2026 10-K grounds a real but bounded defence. On the defence side: Item 1 states that in the manufacturing services market "there are significant barriers to entry in our existing and target markets, including lengthy sales cycles, the need to demonstrate complex precision optical and electro-mechanical engineering and manufacturing capabilities to a prospective customer and the ability to protect a customer's intellectual property," and that qualification of a program "may take three to six months or longer to complete." On the limiting side, the same filing shows the protection does not reach price: gross profit was 12.0% of revenues in FY2026 against 12.1% in FY2025 and 12.4% in FY2024 even as revenue rose 35.7% to $4.64 billion, four customers each exceeded 10% of revenue (Cisco 19.9%, NVIDIA 16.3%, Nokia 10.7%, Amazon 10.5%), and "reliance on a small number of customers gives those customers substantial purchasing power and leverage in negotiating contracts with us." Sales are made on "individual purchase orders that have short lead times and are subject to revision or cancellation," so the qualified program is sticky while the contract is not. |
| Moat type | none The FY2026 10-K's asserted advantage is control from owning its data centers, 'including the associated land, grid connections and substations', which it believes allows it 'to benefit from more sustainable cash flows and operational flexibility relative to operators that rely upon third-party colocation services or short-term land leases'. Its only scale language is a belief that its 'procurement scale, deployment experience and direct control over the data center layer' lets it bring new compute into service 'rapidly and at scale', a deployment-speed claim, and it 'generally target[s]' regions with 'low-cost and attractive renewable energy sources', a siting target rather than a demonstrated cost position. It does not claim a cost or scale lead: it says 'Many of our competitors are larger, have longer operating histories and significantly greater resources than we do' and that certain competitors 'may have access to more competitively priced power, a greater access to power and a better capacity to timely secure grid connections.' There is no network effect or lock-in either, since existing contracts have 'terms ranging from month to month up to five years'. No enumerated moat source is grounded. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. | switching costs The 10-K locates the stickiness in qualification rather than in patents or scale. Customers "do not purchase our services until they qualify the services and satisfactorily complete factory audits and vendor evaluations"; qualification "may take three to six months or longer"; production is transferred "copy-exact: the setup of a production process identical to the one used by our customer"; and the filing's own experience of changing a component source is that it "resulted in our customers or their end customers requiring requalification and validation of components, a process that can often be lengthy and has negatively impacted the timing of our revenue" — the same friction a customer would face moving the program elsewhere. The filing rules out an IP-based moat itself: "Historically, patents have not played a significant role in the protection of our proprietary rights," and any process improvement developed for a customer's product is "immediately assigned to that customer." The Thailand cost base is a genuine advantage but the filing warns it is not durable on its own — "Wage increases may impact our ability to sustain our competitive advantage and may reduce our profit margin." |
| Leadership | behind The 10-K lists IREN's competitors as hyperscalers (Amazon Web Services, Google Cloud, Microsoft Azure, Oracle Cloud) and specialized AI Cloud Services providers (CoreWeave, Nebius, Crusoe, Lambda, Nscale, SpaceX and others). It says IREN began providing AI Cloud Services in 2024 and cites its 'shorter operating history in AI Cloud Services relative to some competitors', and states 'Some of our competitors have longer operating histories, larger customer bases, more comprehensive IP portfolios and patent protections, more design wins, and greater financial, sales, marketing and distribution resources than we do.' Operating AI Cloud Services capacity was approximately 40MW at June 30, 2026. The filing describes a smaller, later entrant that trails some competitors on operating history, customer base and resources, with its progress so far resting on two anchor contracts (a ~$9.7B five-year Microsoft agreement and a ~$3.4B five-year NVIDIA contract) rather than any claimed category position. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. | co leader The leadership claim in the filing is the company's own qualitative assessment: "We believe we are a leader in manufacturing products for the optical communications market," and, on breadth of process technology, "Based on our experience with customers and our qualitative assessment of our capabilities, we believe we provide a broader array of process technologies to the optics industry than any other manufacturing services provider." The same Item 1 names a crowded field against it — "Benchmark Electronics, Inc., Celestica Inc., InnoLight Technology (Suzhou) Ltd., Jabil Inc., Sanmina Corporation, Venture Corporation Limited and Eoptolink Technology Inc., Ltd., as well as the internal manufacturing capabilities of our customers" — and no independent share ranking is given, so the record supports front-of-field standing but not sole primacy. |
| Pricing power | weak The 10-K's risk factors state 'Our competitors' products, services and technologies may be cheaper or provide better functionality or features than ours, which has resulted and may in the future result in lower-than-expected selling prices or demand for our products.' They also say long-term contract pricing 'is generally fixed or agreed at the time of contracting', so if market pricing for comparable capacity rises during a contract's term 'we will not benefit from those increases with respect to capacity already committed under our existing long-term contracts', and that if customers suffer a downturn or discontinue its services it 'may be compelled to offer more flexible terms, lower our prices or risk losing a significant customer.' The stored XBRL fundamentals from this 10-K show FY2026 revenue of about $707.0M against an operating loss of about $1,046.7M, so there is no margin record yet that evidences pricing power. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). | weak Gross profit was 12.0% of revenues in FY2026, 12.1% in FY2025 and 12.4% in FY2024 — flat to down across three years in which revenue grew from $2.88 billion to $4.64 billion — and the FY2026 increase in gross profit is attributed to "sales volume and product mix," not price. Item 1 says so directly: "we expect the prices we charge for our manufactured products to decrease over time (partly as a result of competitive market forces)," with the offset coming from cycle-time, mix, yield and material-cost work rather than from rate. The risk factors add that customer consolidation gives buyers "increased leverage that may result in, among other things, decreases in our average selling prices," and that new competition "could result in price reductions for our services, reduced gross profit margins or loss of market share." |
| Summary | Per its FY2026 10-K, IREN is a vertically integrated AI Cloud Services platform that owns the data center, compute and software layers, underpinned by executed grid connection agreements, letters of agreement or equivalents representing ~5GW and a further multi-GW development pipeline. Its commercial record is concentrated: a five-year Microsoft agreement (~$9.7B total contract value, Horizon 1 delivered and accepted in August 2026, Horizons 2-4 targeted for delivery in phases in calendar Q4 2026) and a five-year ~$3.4B NVIDIA cloud contract together make up a substantial majority of contracted revenue. It holds NVIDIA Preferred Partner and Exemplar Cloud status (HGX B300 and GB300 NVL72) and a strategic partnership intended to support the deployment over time of up to 5GW of NVIDIA DSX-aligned infrastructure, which the filing cites among arrangements that are non-binding or subject to conditions, with no assurance as to the extent of deployments. Against that, the filing names hyperscaler and specialized competitors (AWS, Google Cloud, Azure, Oracle, CoreWeave, Nebius, Crusoe, Lambda, Nscale, SpaceX), many of which it says have greater resources, customers that can use or develop their own solutions, and possible delays to Texas energization from changes to ERCOT's Batch Zero procedures, so the power position is not a demonstrated advantage over rivals and its value depends on execution. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. | Fabrinet is the neutral outsourced factory for complex photonics. The FY2026 10-K describes a business that wins on qualification and IP hygiene rather than on product ownership: a "factory-within-a-factory" that physically segregates each customer's engineers and floor space, copy-exact line transfers, Telcordia-grade environmental qualification, and a claim that "there is no other manufacturing services provider with a similar breadth and depth of optical and electro-mechanical engineering and process technology capabilities that does not directly compete with its customers in their end-markets." That neutrality is claimed as a belief, not demonstrated — the filing's own framing is "we believe" — and Item 1 names the field it is measured against without characterising any of them: "Benchmark Electronics, Inc., Celestica Inc., InnoLight Technology (Suzhou) Ltd., Jabil Inc., Sanmina Corporation, Venture Corporation Limited and Eoptolink Technology Inc., Ltd., as well as the internal manufacturing capabilities of our customers." Once a program is qualified it tends to stay, and "in many cases, we are the sole outsourced manufacturing partner used by our customers for the products that we manufacture for them." What the moat does not buy is margin. Revenue grew 35.7% in FY2026 to $4.64 billion on the AI-datacenter build-out — data center products are now 47.9% of revenue — yet gross margin slipped to 12.0%, and Item 1 concedes the company expects "the prices we charge for our manufactured products to decrease over time." The two live erosion paths are named in the risk factors: customer consolidation that "may result in, among other things, decreases in our average selling prices," and customers who "acquired the capacity to manufacture products in-house." Concentration cuts both ways this year — FY2025 had two customers above 10% of revenue, FY2026 had four, so the book broadened even as its scale grew. |
| Chain position | Downstream AI-cloud operator: owns grid-connected data centers and deploys NVIDIA/AMD GPU systems it rents to hyperscalers, frontier labs, AI developers and enterprises (anchor customers Microsoft and NVIDIA). | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. | A contract manufacturer sitting between optical components and the network and AI-datacenter OEMs whose brands ship the finished box. FY2026 revenue is 47.9% data center, 33.3% communications infrastructure and 18.8% automotive, industrial and other markets (FY2025: 46.2% / 30.7% / 23.1%), with Cisco, NVIDIA, Nokia and Amazon each above 10% of revenue. Fabrinet also integrates one layer down, designing and fabricating its own customized optics and glass — crystals, ferrules, precision glass tubing — at Fuzhou, China and Mountain Lakes, New Jersey, both for its own assemblies and for the merchant market, while volume manufacturing runs from the Pinehurst and Chonburi campuses in Thailand. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |